Skip to main content

Table 2 Drug compliance of each course

From: Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial

Arm A (n = 38)

Arm B (n = 40)

Course no.

No. of patients completing the course

Reason for discontinuation

Course no.

No. of patients completing the course

Reason for discontinuation

1

36 (94.7%)

Adverse event (2)

1

34 (85.0%)

Patient refusal (3)

Adverse event (3)

2

33 (82.5%)

Patient refusal

2

34 (89.5%)

Adverse event (2)

3

31 (77.5%)

Patient refusal

Adverse event

4

29 (72.5%)

Recurrence

Changing hospital

3

34 (89.5%)

 

5

28 (70.0%)

Adverse event

6

27 (67.5%)

Patient refusal

4

31 (81.6%)

Adverse event (2)

Recurrence

7

27 (67.5%)

 

8

25 (62.5%)

Adverse event

Unrelated death

5

31 (81.6%)

 

9

23 (57.5%)

Recurrence (2)

10

22 (55.0%)

Adverse event

6

31 (81.6%)

 

11

21 (52.5%)

Adverse event

12

19 (47.5%)

Adverse event

Recurrence

7

30 (78.9%)

Unrelated death

13

18 (45.0%)

Changing hospital

14

18 (45.0%)

 

8

28 (73.7%)

Patient refusal

Changing hospital

15

18 (45.0%)

 

16

18 (45.0%)